Showing 3991-4000 of 7172 results for "".
- AbbVie Enters Doc Film Biz: Company Releases New Film on Life with Eczemahttps://practicaldermatology.com/news/abbvie-enters-doc-film-biz-company-releases-new-film-on-living-with-eczema/2461609/AbbVie is releasing a new documentary film, “Under My Skin: Untold Stories of Life with Eczema,” which debuted at South by Southwest 2023 in Austin, Texas. The film, directed by Redglass Pictures, features the physical and emotional stories of three ind
- National Society for Cutaneous Medicine Endorses Use of GEP Testing for Melanomahttps://practicaldermatology.com/news/national-society-for-cutaneous-medicine-endorses-use-of-gep-testing-for-melanoma/2461597/The National Society for Cutaneous Medicine now recommends use of gene expression profile (GEP) testing in the clinical assessment and management of cutaneous melanoma (CM). The report provides usage guidelines and a framework for clinicians to integrate GEP testing into their CM
- Memantine May Improve Trichotillomania, Excoriation Disorderhttps://practicaldermatology.com/news/memantine-may-improve-trichotillomania-excoriation-disorder/2461594/The Alzheimer’s disease memantine effectively reduces symptoms of adults with trichotillomania and skin-picking disorder also known as excoriation disorder, new research shows. Researchers honed in on memantine based on earlier findings that revealed disorganized areas of white ma
- Coral-friendly Sunscreen Provides Better UV Protection Than Existing Optionshttps://practicaldermatology.com/news/coral-friendly-sunscreen-provides-better-uv-protection-than-existing-options/2461584/A new coral-friendly polymeric UV filter may be more effective at preventing sunburn than existing sunscreens. Researchers used polymerization to create large molecules that still block UV radiation but are too big to penetrate our skin, coral, and algae. The study was p
- FDA Gives Nod to First Particulate Placental Extracellular Matrix Medical Device for Wound Managementhttps://practicaldermatology.com/news/fda-gives-nod-to-first-particulate-placental-extracellular-matrix-medical-device-for-wound-management/2461574/The U.S. Food and Drug Administration cleared Convatec’s InnovaMatrix PD particulate placental extracellular matrix medical device for wound management. The InnovaMatrix PD medical device joins Convatec’s existing InnovaMatrix AC product as the first and only next-gener
- Dove Partners with LinkedIn in Effort to Help End Race-Based Hair Discrimination in the Workplacehttps://practicaldermatology.com/news/dove-partners-with-linkedin-in-effort-to-help-end-race-based-hair-discrimination-in-the-workplace/2461566/In an effort to help pass “The CROWN Act,” which aims to end race-based hair discrimination, Dove announced it is partnering with LinkedIn. The NEW CROWN 2023 Workplace Research Study, co-commissioned by Dove and LinkedIn, found that black women's hair is 2.5x more
- Neauvia Scores CE Marking Under the European Union’s New MDR for Facial Dermal Filler Linehttps://practicaldermatology.com/news/neauvia-scores-ce-marking-under-the-european-unions-new-mdr-for-facial-dermal-filler-line/2461564/Neauvia scored CE marking under the European Union’s new MDR (Medical Device Regulation) for its range of facial dermal fillers products, making it the first medical aesthetics business to receive such certification in Europe. The new regulation aims to create ‘a robus
- Relief Therapeutics Enrolls First Patients in Proof-of-Concept Trial of Epidermolysis Bullosa Treatmenthttps://practicaldermatology.com/news/relief-therapeutics-enrolls-first-patients-in-proof-of-concept-trial-of-epidermolysis-bullosa-treatment/2461563/Relief Therapeutics announced the first three patients have been enrolled in a proof-of-concept, investigator-initiated study to evaluate RLF-TD011 as a treatment for epidermolysis bullosa (EB). The primary aim of the study will be to assess changes in the skin microbiome (Staphylococcu
- Eye on the AD Pipeline: Dermavant Completes Enrollment of Phase 3 Trials of VTAMA in Adults and Children with ADhttps://practicaldermatology.com/news/eye-on-the-ad-pipeline-dermavant-completes-enrollment-of-phase-3-trials-of-vtama-in-adults-and-children-with-ad/2461561/Dermavant Sciences has completed patient enrollment in its ADORING 1 and 2 Phase 3 clinical trials of VTAMA (tapinarof) cream, 1% for the topical treatment of atopic dermatitis (AD) in adults and children as young as 2 years old. VTAMA cream is a novel, aryl hydrocarbon receptor agonist
- Experts React to Approval of Pfizer’s CIBINQO for Teens With Refractory ADhttps://practicaldermatology.com/news/fda-oks-pfizers-cibinqo-for-teens-with-refractory-ad/2461560/The US FDA has approved a supplemental New Drug Application (sNDA) for CIBINQO (abrocitinib, Pfizer). This move expands the drug's indication to include adolescents (12 to < 18 years) with refractory, moderate to severe atopic dermatitis (AD) whose disease is not adequately contr